Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Mega Lifesciences Public Company Limited (MEGA.BK)
Bangkok, TH
Established in Bangkok, Thailand, in 1982, Mega Lifesciences Public Company Limited, a subsidiary of Unistretch Limited, operates as a comprehensive pharmaceutical and wellness enterprise. Its primary activities encompass the development, promotion, and distribution of a broad spectrum of health-related products, including nutritional supplements, prescription medicines, over-the-counter (OTC) remedies, botanical solutions, vitamins, and everyday consumer goods. The company structures its operations across three main divisions: Brands, Distribution, and Original Equipment Manufacture. Mega Lifesciences offers an extensive array of complementary medicines targeting various health concerns such as bone and joint health, pediatric care, diabetes management, cardiovascular support, digestive and liver wellness, skin health, weight management, overall well-being, men's and women's specific needs, and sports nutrition. Its OTC portfolio addresses common issues like gastrointestinal discomfort and pain. Furthermore, the prescription drug division covers crucial therapeutic areas including iron deficiency, anticoagulation, diabetology, cardiology, dermatology, gastroenterology, neurology, pain relief, osteoporosis, respiratory conditions, urology, oncology, and nephrology. Beyond its proprietary product lines, the company also provides third-party logistical and marketing services. Additionally, Mega Lifesciences is involved in managing wellness centers and offers specialized services in software design, development, and related technological solutions. The company maintains a significant global footprint, with operations spanning the Asia Pacific region, the Middle East, Africa, and the Commonwealth of Independent States.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.31% | +0.00% | +7.35% | -7.59% | +19.67% | +8.96% | +21.67% | -10.98% | +2.82% | +123.93% | +71.36% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 5 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-7.8% Q1'26: +6.2% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-5.2% Q1'26: +32.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+19.1% ★ Q1'26: +17.4% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+20.5% ★ Q1'26: +21.5% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+36.1% ★ Q1'26: +34.9% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.3% Q1'26: +0.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.26× ★ Q1'26: 0.21× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 5 EPS Ana. |
Dec 2027 6 Rev. Ana. 5 EPS Ana. |
Dec 2028 6 Rev. Ana. 6 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
7.94B
est: 7.85B (+1.2%)
|
8.81B
est: 8.72B (+1.1%)
|
9.60B
est: 9.70B (-1.0%)
|
10.34B
est: 10.38B (-0.3%)
|
11.13B
est: 11.07B (+0.6%)
|
12.59B
est: 12.51B (+0.6%)
|
14.14B
est: 14.66B (-3.6%)
|
15.69B
est: 15.36B (+2.1%)
|
15.68B
est: 15.68B (0.0%)
|
15.34B
est: 15.67B (-2.1%)
|
14.15B
est: 14.52B (-2.6%)
|
15.39B
15.11B – 15.76B
+6.0% YoY
|
16.18B
15.74B – 16.83B
+5.1% YoY
|
16.81B
16.69B – 16.94B
+3.9% YoY
|
| EBITDA |
985.78M
est: 1.36B (-27.4%)
|
1.11B
est: 1.51B (-26.6%)
|
1.48B
est: 1.68B (-11.8%)
|
1.59B
est: 1.79B (-11.1%)
|
1.53B
est: 1.91B (-19.9%)
|
2.00B
est: 2.16B (-7.7%)
|
2.58B
est: 2.53B (+1.8%)
|
2.90B
est: 2.66B (+9.0%)
|
2.58B
est: 2.92B (-11.7%)
|
2.67B
est: 2.92B (-8.4%)
|
3.19B
est: 2.70B (+17.8%)
|
2.87B
2.81B – 2.93B
+6.0% YoY
|
3.01B
2.93B – 3.13B
+5.1% YoY
|
3.13B
3.11B – 3.15B
+3.9% YoY
|
| EBIT |
840.53M
est: 1.21B (-30.5%)
|
954.89M
est: 1.34B (-28.9%)
|
1.33B
est: 1.49B (-11.2%)
|
1.44B
est: 1.60B (-9.8%)
|
1.36B
est: 1.71B (-20.1%)
|
1.70B
est: 1.93B (-12.1%)
|
2.31B
est: 2.26B (+2.0%)
|
2.62B
est: 2.37B (+10.8%)
|
2.29B
est: 2.63B (-12.7%)
|
2.39B
est: 2.63B (-8.9%)
|
2.90B
est: 2.43B (+19.3%)
|
2.58B
2.53B – 2.64B
+6.0% YoY
|
2.71B
2.64B – 2.82B
+5.1% YoY
|
2.82B
2.80B – 2.84B
+3.9% YoY
|
| Net Income |
695.75M
est: 612.15M (+13.7%)
|
794.91M
est: 811.56M (-2.1%)
|
1.11B
est: 1.12B (-0.9%)
|
1.21B
est: 1.23B (-2.2%)
|
1.14B
est: 1.14B (-0.2%)
|
1.39B
est: 1.35B (+3.5%)
|
1.95B
est: 1.93B (+1.1%)
|
2.24B
est: 2.30B (-2.6%)
|
1.99B
est: 2.00B (-0.3%)
|
2.01B
est: 2.13B (-5.6%)
|
1.91B
est: 1.91B (+0.0%)
|
2.30B
2.15B – 2.45B
+20.1% YoY
|
2.46B
2.35B – 2.60B
+7.3% YoY
|
2.62B
2.49B – 2.86B
+6.4% YoY
|
| SGA |
2.60B
est: 2.05B (+26.8%)
|
2.58B
est: 2.28B (+13.2%)
|
2.87B
est: 2.53B (+13.4%)
|
3.15B
est: 2.71B (+16.3%)
|
3.10B
est: 2.89B (+7.1%)
|
3.16B
est: 3.27B (-3.2%)
|
3.61B
est: 3.83B (-5.7%)
|
4.19B
est: 4.01B (+4.5%)
|
4.03B
est: 4.26B (-5.4%)
|
4.22B
est: 4.26B (-1.0%)
|
4.31B
est: 3.95B (+9.1%)
|
4.18B
4.11B – 4.28B
+6.0% YoY
|
4.40B
4.28B – 4.58B
+5.1% YoY
|
4.57B
4.54B – 4.61B
+3.9% YoY
|
| EPS |
0.80
est: 0.70 (+13.6%)
|
0.92
est: 0.93 (-1.4%)
|
1.29
est: 1.29 (-0.1%)
|
1.39
est: 1.42 (-2.0%)
|
1.31
est: 1.31 (-0.2%)
|
1.60
est: 1.55 (+3.4%)
|
2.23
est: 2.22 (+0.7%)
|
2.57
est: 2.65 (-3.2%)
|
2.29
est: 2.29 (-0.1%)
|
2.31
est: 2.43 (-4.9%)
|
2.19
est: 2.23 (-1.8%)
|
2.61
2.47 – 2.81
+17.0% YoY
|
2.80
2.69 – 2.98
+7.4% YoY
|
3.06
2.86 – 3.28
+9.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-13 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-12 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-11 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-08 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-06 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-05 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-30 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.03% | 184.5K | 0.65% |
| 2 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.01% | 34.4K | 0.56% |
| 3 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.01% | 51.3K | 0.44% |
| 4 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 94.8K | 0.26% |
| 5 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 42.0K | 0.48% |
| 6 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 273.8K | 0.39% |
| 7 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 265.1K | 0.28% |
| 8 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 7.5K | 0.22% |
| 9 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 22.7K | 0.22% |
| 10 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 12.2K | 0.22% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Deepak Panjwani | Chief Risk & Compliance Officer | — | male |
| Duangnapa Tongsiri | President of Mega We Care Thailand & Head Coach | — | female |
| Francis Rego | Regional Finance Head at Mega LifeSciences Pty. Ltd. | — | — |
| Girish Wadhwa | President of Myanmar & Head Coach | — | male |
| Manoj Gurbuxani | Deputy Chief Financial Officer | — | male |
| Paramjit Singh Sawhney | President of International & Head Coach | — | male |
| Sujintana Boonworapat | Corporate Secretary | — | female |
| Thomas Abraham | CFO, Head Coach & Executive Director | — | male |
| Vivek Dhawan | CEO, Head of ESG, Chief Coach & Executive Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MEGA.BK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
